US Patent

US8802152 — Microporous zirconium silicate for the treatment of hyperkalemia

Composition of Matter · Assigned to ZS Pharma Inc · Expires 2032-04-19 · 6y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel microporous zirconium silicate compositions for removing toxins, such as potassium ions, from the gastrointestinal tract.

USPTO Abstract

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Drugs covered by this patent

Patent Metadata

Patent number
US8802152
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-04-19
Drug substance claim
Yes
Drug product claim
No
Assignee
ZS Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.